COMP <GO>
KRMD vs ABBV // FORWARD P/E MULTIPLE
KORU Medical Systems Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: KRMD 2
— ABBV 8
■ METRIC PARITY
LAST: $3.23 (+0.31%) • MKT CAP: $149.1M
forward-pe
—
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KRMD VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KRMD | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 62.30% | 70.20% | -7.90 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -28.70% | 29.00% | -57.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.31% | 3.47% | -3.16 | ABBV | /fcf-yield <GO> |
| Operating Margin | -7.20% | 24.60% | -31.80 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -6.40% | 6.90% | -13.30 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 22.20% | 8.60% | +13.60 | KRMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.05 | 5.33 | +2.72 | KRMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.1 | 65.1 | -23.00 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $149.1M | $513.86B | -$513.71B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KRMD REV | ABBV REV | KRMD GROSS % | ABBV GROSS % | KRMD FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $41.1M | $61.16B | 62.3% | 70.2% | $462.4K | $17.82B |
| FY 2024 | $33.6M | $56.33B | 63.4% | 70.0% | -$319.7K | $17.83B |
| FY 2023 | $28.5M | $54.32B | — | — | -$4.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KRMD // BETA —
ABBV // BETA 1.15